Mode
Text Size
Log in / Sign up
Phase 4 N=136 Randomized Single-blind Treatment

Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy

Colon Cancer

Enrolled (actual)
136
Serious AEs
0.0%
Results posted
Jun 2016
Primary outcome: Primary: Boston Prep Scale — 7.0; 7.2 units on a scale — p=.45

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
PEG-3350 and Gatorade (Drug); Golytely 4 liters (Drug)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
Temple University
Primary completion
Jul 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Boston Prep Scale
7.0; 7.2 .45
SECONDARY
Sodium Level in mmol/L
138.8; 139.3 .13
SECONDARY
Potassium Level in mmol/L
4.0; 3.9 .31
SECONDARY
Chloride Level in mmol/L
104.1; 104.2 .87
SECONDARY
Bicarbonate Level in mmol/L
26.4; 25.9 .25
SECONDARY
BUN Level in mg/dl
9.0; 9.5 .47
SECONDARY
Creatinine Level in mg/dl
0.9; 1.1 .34
SECONDARY
Glucose Level in mg/dl
98.2; 93.7 .18
SECONDARY
Calcium Level in mg/dl
9.3; 9.3 .75
SECONDARY
Magnesium Level in mg/dl
2.1; 2.1 .92
SECONDARY
Phosphorus Level in mg/dl
3.4; 3.5 .60

Summary

A major limitation to the widespread acceptance of colonoscopy as a procedure to screen for colorectal cancer is the laxative preparation. Phosphate-based preps (e.g. Fleets Phosphosoda) are now used on a limited basis because of their known association with renal injury. Polyethylene glycol (PEG) mixed with a balanced electrolyte solution (e.g. Golytely) has been used for over two decades for colon cleansing. The mixture is not very palatable due to the electrolyte additives which include sodium sulfate. To overcome the limitation of existing preps, gastroenterologists and colorectal surgeons worldwide have been using PEG powder alone (same quantity as found in Golytely prep) not mixed with electrolytes (Glycolax or Miralax) and dissolving this into 64 ounces of Gatorade. Conservatively, we estimate that 25% of colonoscopies in the US are being done with this prep. Anecdotally there have been reports (case series) that it is far more palatable and the prep is equally efficacious. The active ingredient, PEG, is not changed and therefore this is not surprising. The issue at present is that there has never been a blinded study to confirm these claims. This study will compare the efficacy of the two preps. There is no funding. The investigators will charge insurance companies for the prep - this is our current practice. The procedures will be done on healthy individuals referred for colon cancer screening and the exam will be billed to their insurance. There will be no patient honorarium. The investigators will check electrolytes to be sure patients do not develop hypokalemia with the Gatorade prep.

Eligibility Criteria

Inclusion Criteria

All adults undergoing average risk colon cancer screening (ages 40-75 years old)

•Able to provide informed consent

Exclusion Criteria

  • A history of constipation
  • Patients who use medications to assist with a bowel movement such as osmotic, stimulant, or cathartic laxatives (including "colon cleansers")
  • Diabetes or glucose intolerance
  • Patients with severe underlying renal or hepatic impairment
  • Pregnant women - pregnancy test performed on all menstruating women before procedure.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01170754). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search